Thymosin Alpha-1 | Reviews, Clinical Trials, and Safety

Treatment of hepatitis C: Ta1 has shown potential as an immunomodulatory peptide in improving treatment outcomes for hepatitis C virus (HCV) when used in combination with standard care. Its immunomodulatory properties, including T-cell function enhancement and cytokine production regulation, may enhance treatment response and reduce liver inflammation [5].

However, clinical trials combining Ta1 with interferon-based therapies, the standard treatment for HCV, have not provided definitive evidence supporting its efficacy. Despite these findings, the potential of Ta1 as an adjunctive therapy for HCV remains a topic of investigation [6].

Treatment of hepatitis B: Zhang et al. (2009) conducted a comprehensive literature review to evaluate the efficacy of combining lamivudine and thymosin alpha-1 in treating hepatitis B virus (HBV) infection. The study included eight trials involving 583 patients.

The results demonstrated that the combination of lamivudine and Ta1 yielded significant improvements compared to lamivudine treatment alone. Specifically, there were notable advancements in the normalization rate of alanine aminotransferase (ALT), the virological response rate, and the hepatitis B e antigen (HBeAg) seroconversion rate.

ALT normalization signifies enhanced liver function, while virological response and HBeAg seroconversion indicate reduced viral replication and transition to an inactive HBV carrier state. The favorable outcomes in these aspects suggest that adding Ta1 to lamivudine treatment may augment therapeutic effects in patients with HBV infection [7].

COVID-19 treatment: In a pilot trial conducted by Shehadeh et al. (2022), the efficacy and safety of thymalfasin, a synthetic form of thymosin alpha-1, were evaluated in comparison to the standard of care for hospitalized patients with COVID-19 who experienced hypoxemia and lymphocytopenia.

The trial was a prospective, open-label, randomized study. The results indicated that treatment with Ta1 led to a faster increase in CD4+ T-cell count among patients who required low-flow oxygen support at baseline, compared to the standard of care. This finding suggests that Ta1 may play a role in managing hospitalized COVID-19 patients with hypoxemia and lymphocytopenia [9].

Immunodeficiency disorders: Thymosin alpha-1 has also shown the potential to modulate the immune response against viral infections such as HIV-1 and HTLV-1. In an in vitro study conducted by Matteucci et al. (2015), Ta1 was found to inhibit HIV-1 infection of macrophages (MDMs) and PBMCs, as well as HTLV-1 infection of PBMCs, while positively impacting gene expression in immune cells associated with HIV infection [10].

Vaccine adjuvant: The utilization of thymosin alpha-1 as an adjuvant to the influenza vaccine has demonstrated encouraging outcomes, particularly in elderly and immunocompromised populations. Studies indicate that thymosin alpha-1 can enhance the immune response generated by the influenza vaccine, improving immunogenicity [11].

Bacterial and fungal infections:Thymosin alpha-1 has been investigated for its potential therapeutic benefits in various infectious conditions, including Pseudomonas infections and infections following bone marrow transplantation. In the case of Pseudomonas infections, Ta1 has shown promising immunomodulatory effects that can enhance the immune response against the bacteria [12].

Thymosin alpha-1 exhibits immunomodulatory effects that contribute to the generation of an antifungal immune response, as well. It is shown to enhance the development and function of Th1 and regulatory T (Treg) cells, which help to balance inflammation and promote an effective antifungal response [13].

Other possible applications: Thymosin alpha-1 is also under investigation for its utility in treating chronic fatigue syndrome and psoriatic arthritis. It is of further interest for its purported anti-aging and neuroprotective properties.